Cambrex, a prominent global contract development and manufacturing organization (CDMO), has announced a new partnership with Eli Lilly and Company (Lilly) to facilitate speedy access to clinical development resources for Lilly’s biotech partners.
In this collaboration, Cambrex will join forces with Lilly Catalyze360-ExploR&D, the company’s division focused on early-stage external innovation and partnerships. This will enhance their drug substance, drug product, analytical service lab offerings, as well as R&D expertise, all for the benefit of Lilly Catalyze360’s biotech affiliates.
“We are thrilled to contribute to Lilly’s goal of empowering external biotech partners to accelerate their product development,” said Brandon Fincher, President of Early Stage Development & Testing at Cambrex. “Our Longmont facility is fully equipped to support the progression of early-stage small molecules into clinical trials, bringing together speed, adaptability, and scientific excellence. We eagerly anticipate assisting Lilly Catalyze360 partners in efficiently moving towards successful product outcomes.”
Lilly Catalyze360 is committed to propelling scientific advancement and fostering emerging therapies through three core areas: Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D. Through this strategic partnership, Cambrex will work with ExploR&D, a vital external innovation pillar at Lilly that combines business insight, scientific expertise, and top-tier research and development to quicken partner innovations.
The primary operations under this collaboration will be based in Longmont, Colorado, with additional backing from Cambrex’s broader network as needed. The Longmont site specializes in the early-stage development of new investigational drugs, ranging from process and drug substance development to formulation and drug product manufacturing. It also includes capacities for both non-GMP and cGMP production, as well as holistic analytical development and cGMP testing.
Cambrex is an esteemed global leader in contract development and manufacturing, offering comprehensive drug substance development and production across different stages of drug lifecycle, alongside thorough analytical and IND support services.
With more than four decades of industry experience and a team of 2,000 proficient global experts, Cambrex provides a wide array of specialized drug substance technologies and expertise, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent active pharmaceutical ingredients (APIs).